MedTrace Logo

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

NCT07672223 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 570

Last updated 2026-06-26

No results posted yet for this study

Summary

The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with. with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR).

Conditions

Interventions

DRUG

SYS6010

SYS6010

DRUG

Enlonstobart

Enlonstobart

DRUG

Tislelizumab

administered via Intravenous (IV) injection

DRUG

Toripalimab ±+platinum-based doublet chemotherapy

Cisplatin; Carboplatin; Pemetrexed; Paclitaxel;

DRUG

Durvalumab

Durvalumab

DRUG

Pembrolizumab

Pembrolizumab

DRUG

Nivolumab

Nivolumab

Sponsors & Collaborators

  • CSPC Megalith Biopharmaceutical Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-25
Primary Completion
2029-09-30
Completion
2031-11-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07672223 on ClinicalTrials.gov